8-K: Silexion Submits Phase 2/3 Trial Application for SIL204

Silexion Therapeutics announced the submission of its Phase 2/3 clinical trial application in Israel for SIL204, targeting locally advanced pancreatic cancer.

Summary

• Silexion Therapeutics Corp has submitted a Phase 2/3 Clinical Trial Application (CTA) to Israel for its lead product candidate, SIL204, for the treatment of locally advanced pancreatic cancer (LAPC).
• The submission follows positive Scientific Advice from the German Federal Institute for Drugs and Medical Devices (BfArM) and successful toxicology studies confirming no systemic organ toxicity.
• Preclinical data for SIL204 demonstrated up to 99.7% inhibition across multiple KRAS mutations and cancer types.
• The company plans to initiate the Phase 2/3 clinical trial in the second quarter of 2026.
• Regulatory filings in Germany and the European Union are planned for Q1 2026, with U.S. expansion anticipated after the safety run-in in Israel and Germany.
• The Israeli portion of the trial will be conducted in collaboration with Sheba Medical Center.
• SIL204 is a next-generation siRNA therapy designed to silence mutated KRAS oncogenes, utilizing a dual-route administration strategy (intratumoral and systemic).

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful achievement of a key regulatory milestone, strong preclinical data, positive regulatory feedback, and clear plans for advancing a promising therapy for a high-unmet-need cancer. The company is on track with its stated goals, which is a strong indicator of operational execution.

Positives

• Submission of the Phase 2/3 CTA to Israel marks a significant regulatory milestone, advancing SIL204 towards human trials.
• Positive Scientific Advice received from German regulatory authorities (BfArM) supports the clinical development plan.
• Successful completion of two species toxicology studies confirmed no systemic organ toxicity, bolstering the safety profile.
• Strong preclinical data showed up to 99.7% cancer cell inhibition across various KRAS mutations and cancer types.
• Collaboration with Sheba Medical Center, a top-ranked hospital, enhances the credibility and execution of the Israeli trial portion.
• The company achieved its final milestone for 2025 with this submission, demonstrating strong execution.

Risks

• Silexion's ability to successfully complete preclinical studies and initiate clinical trials.
• Silexion's strategy, future operations, financial position, projected costs, prospects, and plans may not materialize as expected.
• The impact of the regulatory environment and compliance complexities could hinder progress.
• Expectations regarding future partnerships or other relationships with third parties may not be met.
• Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital, pose a risk.
• Silexion's ability to maintain its Nasdaq listing is a factor.
• Actual results or events may differ materially from forward-looking statements due to various uncertainties.

Future Outlook

Silexion Therapeutics plans to initiate its Phase 2/3 clinical trial for SIL204 in Q2 2026, following regulatory filings in Germany and the EU in Q1 2026. Expansion to U.S. clinical sites is anticipated after the completion of the safety run-in in Israel and Germany. The company believes SIL204 is well-positioned to address the critical unmet need in locally advanced pancreatic cancer.

Management Comments

• "The submission of the regulatory request to initiate the human studies in Israel with Sheba Medical Center represents an important moment for Silexion and marks what we see as the transition of SIL204 from preclinical development into advanced clinical trials."
• "With preclinical data having previously demonstrated up to 99.7% inhibition across multiple KRAS mutations and cancer types, positive response feedback from German authorities, and a completed safety package, we believe SIL204 is well-positioned to address the critical unmet need in locally advanced pancreatic cancer a disease with limited treatment options and poor survival outcomes."
• "This submission marks our final milestone for 2025, and I am proud of our team's exceptional execution throughout this transformative year. We look forward to initiating the Phase 2/3 trial in the second quarter of 2026."

Industry Context

Locally advanced pancreatic cancer (LAPC) represents a significant unmet medical need with limited treatment options and poor survival outcomes. The mutated KRAS oncogene is the most common oncogenic driver in human cancers, making therapies targeting KRAS, like Silexion's SIL204, highly relevant in the oncology landscape. The advancement of an RNA-based therapy into late-stage clinical trials for such a challenging cancer positions Silexion at the forefront of innovative oncology treatments.

Comparison to Industry Standards

• Sheba Medical Center, where the Israeli portion of the trial will be conducted, is ranked among the top ten hospitals worldwide by Newsweek, indicating a high standard for clinical trial execution.
• The company's first-generation product showed a positive trend in a Phase 2a clinical trial compared to chemotherapy alone, suggesting a foundational capability in developing effective cancer therapies, though specific comparative data for SIL204 against current LAPC treatments or other KRAS inhibitors are not detailed in this filing.

Stakeholder Impact

• **Shareholders:** Positive news regarding clinical development progress could increase investor confidence and potentially lead to share price appreciation, though future capital requirements are noted as a risk.
• **Patients:** The advancement of SIL204 offers potential new treatment options for patients suffering from locally advanced pancreatic cancer, a disease with limited current therapies and poor outcomes.
• **Employees:** Successful progression of the lead candidate validates the company's research and development efforts, potentially boosting morale and job security.
• **Regulatory Authorities:** The submission and planned trials demonstrate compliance with regulatory pathways and commitment to bringing new therapies to market.

Next Steps

• Initiate regulatory applications in Germany and the European Union in Q1 2026.
• Initiate the Phase 2/3 clinical trial for SIL204 in Q2 2026.
• Expand clinical development to U.S. sites following completion of the safety run-in in Israel and Germany.

Key Dates

Recommendation

The submission of a Phase 2/3 CTA for a novel RNA-based therapy targeting KRAS mutations in a high-unmet-need cancer like LAPC is a significant de-risking event and a strong positive catalyst. Coupled with robust preclinical data, positive regulatory feedback, and a clear clinical timeline, this indicates strong operational execution and potential for future value creation. While risks inherent to clinical development and future capital needs exist, the current progress suggests a favorable outlook for long-term investors, warranting a 'buy' recommendation for those with a higher risk tolerance in the biotech sector.

Keywords

Silexion Therapeutics, SIL204, Pancreatic Cancer, Locally Advanced Pancreatic Cancer, LAPC, KRAS, siRNA therapy, Clinical Trial Application, Phase 2/3 trial, Oncology, Biotechnology, RNA-based therapies, Drug development, SEC filing, 8-K